Raymond Goodrich

Founder at PhotonPharma, Inc.

Health Technology

Profile

Raymond Goodrich is the founder of PhotonPharma, Inc. and currently holds the title of CSO & Vice President-Research & Development at the company.

Raymond Goodrich active positions

Companies	Position	Start
PhotonPharma, Inc. PhotonPharma, Inc. BiotechnologyHealth Technology PhotonPharma, Inc. is a company that is developing a personalized therapeutic cancer vaccine called Innocell. The company is based in Fort Collins, CO, at the Research Innovation Center of Colorado State University. The vaccine is designed using autologous tumor tissue and a photochemical inactivation platform that uses riboflavin and UV light to render tumor cells incapable of replication while still being able to metabolize, express proteins, present antigen, and stimulate immune recognition and response mechanisms. The company has demonstrated the ability of this technology to prevent metastatic tumor formation, reduce the growth of tumors, and stimulate cellular immune response pathways in preclinical development animal models. The company was founded in 2018 by Raymond Goodrich, and the CEO is Alan S. Rudolph.	Founder	-

All active positions of Raymond Goodrich

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Raymond Goodrich's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	1
PhotonPharma, Inc. PhotonPharma, Inc. BiotechnologyHealth Technology PhotonPharma, Inc. is a company that is developing a personalized therapeutic cancer vaccine called Innocell. The company is based in Fort Collins, CO, at the Research Innovation Center of Colorado State University. The vaccine is designed using autologous tumor tissue and a photochemical inactivation platform that uses riboflavin and UV light to render tumor cells incapable of replication while still being able to metabolize, express proteins, present antigen, and stimulate immune recognition and response mechanisms. The company has demonstrated the ability of this technology to prevent metastatic tumor formation, reduce the growth of tumors, and stimulate cellular immune response pathways in preclinical development animal models. The company was founded in 2018 by Raymond Goodrich, and the CEO is Alan S. Rudolph.	Health Technology